Cablivi 10 mg Caplacizumab

Description

Cablivi 10mg (caplacizumab) is approved for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP) and is available in powder form or solution for injection for use in conjunction with plasma exchange and immunosuppressive therapy. The drug used in acquired thrombotic thrombocytopenic purpura (aTTP) disease indications is produced by Ablynx NV. Approved by the European Medicine Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Cablivi 10mg is administered intravenously, that is, by administering the drug directly into the vein.